Your browser is no longer supported. Please, upgrade your browser.
TBIO [NASD]
Translate Bio, Inc.
Index- P/E- EPS (ttm)-1.11 Insider Own0.70% Shs Outstand73.18M Perf Week-1.41%
Market Cap1.71B Forward P/E223.59 EPS next Y0.10 Insider Trans-30.44% Shs Float64.99M Perf Month-10.07%
Income-64.30M PEG- EPS next Q-0.24 Inst Own93.40% Short Float8.72% Perf Quarter67.86%
Sales91.30M P/S18.77 EPS this Y-1.70% Inst Trans-0.21% Short Ratio4.86 Perf Half Y22.18%
Book/sh5.00 P/B4.61 EPS next Y111.80% ROA-12.80% Target Price31.88 Perf Year164.71%
Cash/sh9.06 P/C2.54 EPS next 5Y- ROE-27.50% 52W Range6.80 - 28.09 Perf YTD24.96%
Dividend- P/FCF7.41 EPS past 5Y- ROI-75.10% 52W High-18.01% Beta-
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin- 52W Low238.68% ATR1.66
Employees93 Current Ratio5.70 Sales Q/Q5148.50% Oper. Margin-72.70% RSI (14)56.60 Volatility5.82% 6.74%
OptionableYes Debt/Eq0.00 EPS Q/Q155.50% Profit Margin-70.40% Rel Volume0.43 Prev Close22.53
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume1.17M Price23.03
Recom1.60 SMA206.98% SMA5010.24% SMA20038.43% Volume507,378 Change2.22%
Oct-05-20Initiated Goldman Buy $19
Jul-07-20Reiterated H.C. Wainwright Buy $18 → $32
Jul-06-20Initiated William Blair Outperform
Jun-26-20Initiated SunTrust Buy $40
Jul-22-19Initiated Jefferies Buy $20
Jun-18-19Initiated ROTH Capital Buy $25
Dec-24-18Initiated H.C. Wainwright Buy $21
Jul-23-18Initiated Leerink Partners Outperform $24
Jul-23-18Initiated Evercore ISI Outperform $25
Jul-23-18Initiated Citigroup Buy $20
Jan-07-21 07:30AM  
Dec-22-20 04:20PM  
Dec-02-20 11:17AM  
Nov-30-20 01:56PM  
Nov-17-20 06:04AM  
Nov-12-20 07:30AM  
Nov-09-20 04:12PM  
Nov-05-20 04:21PM  
Nov-02-20 04:33PM  
Nov-01-20 10:03AM  
Oct-16-20 01:01PM  
Oct-15-20 04:23PM  
01:53PM  
08:00AM  
08:00AM  
Oct-11-20 11:01AM  
Oct-07-20 04:05PM  
12:07PM  
Sep-29-20 04:05PM  
Sep-28-20 06:42PM  
Sep-17-20 01:12PM  
Sep-08-20 07:30AM  
Sep-03-20 04:12PM  
07:30AM  
Aug-14-20 04:55PM  
Aug-06-20 04:14PM  
Jul-31-20 04:55PM  
Jul-30-20 03:52PM  
11:30AM  
Jul-23-20 12:45PM  
Jul-22-20 12:33PM  
Jul-20-20 04:05PM  
Jul-14-20 11:30AM  
Jul-08-20 09:05AM  
Jul-02-20 10:38PM  
Jul-01-20 06:03PM  
10:35AM  
Jun-29-20 08:49AM  
Jun-25-20 11:15PM  
09:36PM  
03:26PM  
07:02AM  
Jun-24-20 04:18PM  
09:33AM  
09:29AM  
Jun-23-20 02:38PM  
01:42PM  
11:40AM  
10:38AM  
10:28AM  
07:57AM  
06:21AM  
03:57AM  
01:48AM  
01:21AM  
12:59AM  
Jun-14-20 08:24PM  
11:16AM  
Jun-03-20 11:41AM  
May-28-20 07:30AM  
May-14-20 11:51AM  
08:47AM  
May-12-20 04:05PM  
May-08-20 06:16PM  
May-07-20 04:26PM  
12:30PM  
Apr-26-20 04:55AM  
Apr-20-20 06:12PM  
Apr-17-20 11:35AM  
Apr-14-20 04:41PM  
Mar-30-20 10:41AM  
08:47AM  
Mar-27-20 04:33PM  
04:10PM  
02:20PM  
08:02AM  
02:00AM  
Mar-26-20 04:30PM  
04:30PM  
Mar-12-20 08:35PM  
04:45PM  
12:30PM  
Feb-26-20 07:30AM  
Feb-19-20 07:30AM  
Dec-14-19 05:18PM  
Dec-12-19 04:15PM  
Dec-10-19 12:22PM  
Nov-27-19 09:45AM  
Nov-14-19 11:56AM  
Nov-13-19 07:30AM  
Nov-06-19 07:25PM  
04:11PM  
Oct-31-19 12:15PM  
Oct-30-19 10:56AM  
Oct-01-19 07:30AM  
Sep-30-19 07:30AM  
Sep-24-19 07:14PM  
Sep-23-19 01:16PM  
Sep-17-19 09:06PM  
04:01PM  
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Renaud Ronald C JRChief Executive Officer, Pres.Jan 14Option Exercise7.395,63941,673494,205Jan 14 07:59 PM
FORMELA JEAN FRANCOISDirectorDec 22Sale25.0782,5652,069,87043,940Dec 23 06:07 PM
FORMELA JEAN FRANCOISDirectorDec 21Sale25.5056,5361,441,928126,505Dec 23 06:07 PM
Renaud Ronald C JRChief Executive Officer, Pres.Nov 16Option Exercise7.3953,007391,725488,566Nov 18 07:30 PM
FORMELA JEAN FRANCOISDirectorAug 27Sale14.3810,097145,2173,833,122Aug 27 08:14 PM
FORMELA JEAN FRANCOISDirectorAug 26Sale14.8044,381656,7463,843,219Aug 27 08:14 PM
FORMELA JEAN FRANCOISDirectorAug 25Sale15.0034,410516,1603,887,600Aug 27 08:14 PM
Shire Human Genetic Therapies,10% OwnerJun 30Sale20.686,824,992141,140,8350Jun 30 08:24 PM
BAUPOST GROUP LLC/MA10% OwnerJun 26Buy22.00500,00011,000,00018,044,239Jun 30 05:37 PM
Shire Human Genetic Therapies,10% OwnerJun 03Sale19.7540,086791,6996,824,992Jun 05 09:52 AM
Shire Human Genetic Therapies,10% OwnerJun 02Sale19.76105,3952,082,9036,865,078Jun 03 06:08 AM
Shire Human Genetic Therapies,10% OwnerJun 01Sale19.86108,4722,154,1216,970,473Jun 03 06:08 AM